Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Joerg Huwyler is active.

Publication


Featured researches published by Joerg Huwyler.


Bioorganic & Medicinal Chemistry Letters | 2010

Discovery of carmegliptin: A potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

Patrizio Mattei; Markus Boehringer; Patrick Di Giorgio; Holger Fischer; Michael Hennig; Joerg Huwyler; Buelent Kocer; Bernd Kuhn; Bernd Michael Loeffler; Alexander Macdonald; Robert Narquizian; Etienne Rauber; Elena Sebokova; Urs Sprecher

Design, synthesis, and SAR are described for a class of DPP-IV inhibitors based on aminobenzo[a]quinolizines with non-aromatic substituents in the S1 specificity pocket. One representative thereof, carmegliptin (8p), was chosen for clinical development. Its X-ray structure in complex with the enzyme and early efficacy data in animal models of type 2 diabetes are also presented.


Bioorganic & Medicinal Chemistry Letters | 2010

Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives : Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists

Thomas Johannes Woltering; Juergen Wichmann; Erwin Goetschi; Frédéric Knoflach; Theresa M. Ballard; Joerg Huwyler; Silvia Gatti

This study completes a series of papers devoted to the characterization of the non-competitive mGluR2/3 antagonist properties of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives with particular emphasis on derivatizations compatible with brain penetration and in vivo activity. Especially the compounds bearing a para-pyridine consistently showed in vivo activity in rat behavioral models after oral administration, for example, blockade of the mGluR2/3 agonist LY354740-induced hypoactivity and improvement of a working memory deficit induced either by LY354740 or scopolamine in the delayed match to position task (DMTP). Moreover, combination studies with a cholinesterase inhibitor show apparent synergistic effects on working memory impairment induced by scopolamine.


Bioorganic & Medicinal Chemistry Letters | 2010

Aryl- and heteroaryl-substituted aminobenzo[a]quinolizines as dipeptidyl peptidase IV inhibitors.

Markus Boehringer; Holger Fischer; Michael Hennig; Daniel Hunziker; Joerg Huwyler; Bernd Kuhn; Bernd Michael Loeffler; Thomas Luebbers; Patrizio Mattei; Robert Narquizian; Elena Sebokova; Urs Sprecher; Hans Peter Wessel

Synthesis and SAR are described for a structurally distinct class of DPP-IV inhibitors based on aminobenzo[a]quinolizines bearing (hetero-)aromatic substituents in the S1 specificity pocket. The m-(fluoromethyl)-phenyl derivative (S,S,S)-2g possesses the best fit in the S1 pocket. However, (S,S,S)-2i, bearing a more hydrophilic 5-methyl-pyridin-2-yl residue as substituent for the S1 pocket, displays excellent in vivo activity and superior drug-like properties.


Journal of Pharmacology and Experimental Therapeutics | 2000

Evidence That Nicotinic α7 Receptors Are Not Involved in the Hyperlocomotor and Rewarding Effects of Nicotine

Andrew J. Grottick; Gerhard Trube; William A. Corrigall; Joerg Huwyler; Parichehr Malherbe; Rene Wyler; Guy A. Higgins


Neuropharmacology | 2003

Evaluation of the NR2B-selective NMDA receptor antagonist Ro 63-1908 on rodent behaviour: evidence for an involvement of NR2B NMDA receptors in response inhibition.

Guy A. Higgins; Theresa M. Ballard; Joerg Huwyler; John A. Kemp; Rammy Gill


Bioorganic & Medicinal Chemistry Letters | 2005

9H-Xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl- and (2H-tetrazol-5-yl)-amides as potent, orally available mGlu1 receptor enhancers

Eric Vieira; Joerg Huwyler; Synese Jolidon; Frédéric Knoflach; Vincent Mutel; Juergen Wichmann


Archive | 2001

Prodrugs to nmda receptor ligand

Alexander Alanine; Bernd Buettelmann; Holger Fisher; Neidhart Marie-Paule Heitz; Joerg Huwyler; Georg Jaeschke; Emmanuel Pinard; Rene Wyler


Archive | 2003

OXAZOLES AS MGLUR1 ENHANCER

Joerg Huwyler; Frédéric Knoflach; Eric Vieira; Juergen Wichmann


Archive | 2002

PRODRUGS TO D-PROLINES

Joerg Huwyler; Roland Jakob-Roetne; Sonia Maria Poli


Archive | 2006

Treatment of neurodegenerative disorders

Anton Haselbeck; Frank Herting; Joerg Huwyler; Michael Jarsch

Collaboration


Dive into the Joerg Huwyler's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge